NextFin news, Two Canadian men with spinal cord injuries underwent successful Neuralink brain chip implant surgeries at Toronto Western Hospital on Wednesday, August 27, and Friday, September 3, 2025, respectively. The procedures, led by neurosurgeon Dr. Andres Lozano, represent the first Neuralink clinical trials conducted outside the United States.
The patients, both approximately 30 years old and from Ontario and Alberta, suffer from quadriplegia with limited or no hand movement. The implanted electrodes target the motor cortex to capture neural signals, which are decoded by artificial intelligence to allow the patients to control a computer cursor through thought alone.
Dr. Lozano reported that the first patient was able to move the cursor within minutes after surgery, demonstrating rapid signal decoding and translation into computer actions. Both patients were discharged the morning after their respective surgeries.
The clinical trial in Canada will monitor the patients for at least one year to assess the safety and effectiveness of the wireless brain-computer interface (BCI) device. The study will also evaluate potential side effects such as seizures, infections, or strokes. Up to four additional patients with spinal cord injuries or Amyotrophic Lateral Sclerosis (ALS) may be enrolled in the trial.
Neuralink, founded by Elon Musk, first introduced the brain chip technology publicly in 2020 and began human trials in the U.S. in 2023. The Canadian surgeries mark an expansion of the company’s clinical research to international sites including the United Kingdom and the United Arab Emirates.
The technology aims to restore communication and control capabilities to people with paralysis by bypassing damaged neural pathways. In the coming months, the Canadian patients will learn to type and play video games using the implant, with future applications potentially including wheelchair or robot control.
Barry Munro, chief development officer of the Canadian Spinal Research Organization and a quadriplegic himself, cautioned that while the technology shows promise, realistic expectations are necessary as the field continues to develop.
Elon Musk and Neuralink’s leadership expressed optimism about the progress on social media, highlighting the significance of extending the technology’s reach beyond the U.S.
This report is based on information from The Canadian Press, Neuralink’s official announcements, and statements from the surgical team at Toronto Western Hospital.
Explore more exclusive insights at nextfin.ai.
